A Study of SGB-7342 in Subjects With Obesity or Overweight
A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-7342 in Subjects With Obesity or Overweight
1 other identifier
interventional
45
0 countries
N/A
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of subcutaneously administered SGB-7342 in adult subjects with obesity and overweight.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_1
Started Jan 2026
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 23, 2025
CompletedFirst Posted
Study publicly available on registry
January 8, 2026
CompletedStudy Start
First participant enrolled
January 12, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 28, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
April 14, 2027
January 9, 2026
January 1, 2026
10 months
December 23, 2025
January 7, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Number of Participants with Adverse Events (AEs)
up to approximately 6 months
Secondary Outcomes (3)
Maximum Observed Plasma Concentration (Cmax)
up to approximately 3 days
Area Under the Concentration-time Curve (AUC)
up to 3 days
Weight change from baseline
up to approximately 12 months
Study Arms (2)
SGB-7342
EXPERIMENTALSGB-7342-Matching placebo
PLACEBO COMPARATORInterventions
Normal saline (0.9% NaCl) in a matching volume, SC injection, single dose
Eligibility Criteria
You may qualify if:
- Body Mass Index (BMI) within the range of 26.0 to 35.0 kg/m²
- Have a stable body weight within 3 months
- Participants must agree to use adequate contraception from signing the informed consent until 6 months after completion of the follow-up visit.
- Willing to comply with the protocol required visit schedule and visit requirements and provide written informed consent.
You may not qualify if:
- A history of or a current surgical or medical condition that, in the opinion of the Investigator, may put the subject at significant risk (according to Investigator's judgment) or interfere with the subject's participation in the clinical study.
- Use of GLP-1R agonists for any indication within 6 months prior to administering the investigational drug.
- Use of non-GLP1R medications for weight loss within 3 months prior to administering the investigational drug.
- Alanine aminotransferase (ALT), total bilirubin (TBIL), aspartate aminotransferase (AST)\> 1.5 × ULN, and deemed clinically significant by the Investigators
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 23, 2025
First Posted
January 8, 2026
Study Start
January 12, 2026
Primary Completion (Estimated)
October 28, 2026
Study Completion (Estimated)
April 14, 2027
Last Updated
January 9, 2026
Record last verified: 2026-01